Table 1. Comparison of Features Among Groups of Treatment Actually Received and Groups of Best Potential Treatments.
| Features | Treatment received | Best potential treatmenta | ||||||
|---|---|---|---|---|---|---|---|---|
| No. (%) | P value | No. (%) | P value | |||||
| Reoperative hepatectomy or thermoablation (n = 293) | Sorafenib (n = 188) | Chemoembolization (n = 220) | Reoperative hepatectomy or thermoablation (611 [87.2%]) | Sorafenib (37 [5.2%]) | Chemoembolization (53 [7.6%]) | |||
| Actual treatment | NA | .01 | ||||||
| Reoperative hepatectomy or thermoablation | NA | NA | NA | 247 (40.4) | 16 (43.2) | 30 (56.6) | ||
| Sorafenib | NA | NA | NA | 171 (28.0) | 13 (35.1) | 4 (7.5) | ||
| Chemoembolization | NA | NA | NA | 193 (31.6) | 8 (21.6) | 19 (35.8) | ||
| Age at recurrence, median (IQR), y | 72.90 (66.93-76.59) | 71.26 (63.32-76.97) | 72.82 (66.56-77.16) | .10 | 71.59 (64.76-76.06) | 78.52 (75.28-83.38) | 77.02 (73.89-80.46) | <.001 |
| Female | 65 (22.2) | 45 (23.9) | 41 (18.6) | .41 | 124 (20.3) | 13 (35.1) | 14 (26.4) | .07 |
| Male | 228 (77.8) | 143 (76.1) | 179 (81.4) | 487 (79.7) | 24 (64.9) | 39 (73.6) | ||
| Cirrhosis | 194 (67.4) | 123 (65.8) | 140 (63.6) | .68 | 412 (67.4) | 31 (83.8) | 18 (34.0) | <.001 |
| Child-Pugh class B | 11 (6.0) | 7 (5.7) | 10 (7.4) | .84 | NA | NA | NA | NA |
| No. of recurrence nodules | ||||||||
| >1 | 70 (24.5) | 120 (74.1) | 123 (67.2) | <.001 | 340 (55.6) | 18 (48.6) | 24 (45.3) | .27 |
| Median (IQR) | 1 (1-1) | 2 (1-5) | 2 (1-4) | <.001 | 2.00 (1.00-3.00) | 1.00 (1.00-2.00) | 1.00 (1.00-2.00) | .03 |
| Bilobar recurrence | 31 (13.2) | 49 (49.5) | 68 (42.2) | <.001 | 165 (27.0) | 21 (56.8) | 36 (67.9) | <.001 |
| Size, cm | ||||||||
| ≥5 | 21 (7.9) | 36 (23.4) | 26 (15.0) | <.001 | 95 (15.5) | 3 (8.1) | 2 (3.8) | .03 |
| Median (IQR) | 2 (1.5-2.5) | 2.5 (1.5-4.4) | 2 (1.5-3.4) | <.001 | 2.00 (1.50-3.30) | 2.40 (1.60-3.30) | 1.50 (1.00-2.00) | <.001 |
| MVI | 98 (39.2) | 78 (47.0) | 75 (41.2) | .28 | 258 (42.2) | 19 (51.4) | 19 (35.8) | .34 |
| Extrahepatic recurrence | 28 (9.6) | 61 (33.9) | 11 (5.2) | <.001 | 89 (14.6) | 16 (43.2) | 0 | <.001 |
| TTR, median (IQR), months | 17.87 (7.93-34.46) | 10.46 (5.05-30.08) | 13.26 (6.79-23.34) | .001 | 15.11 (6.57-28.98) | 6.79 (2.43-17.64) | 21.90 (10.98-41.41) | <.001 |
Abbreviations: MVI, microvascular invasion; NA, not applicable; SAR, survival after recurrence; TTR, time to recurrence (from first surgery).
a
The treatment leading to the highest SAR for each patient.